Prostate Health - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Prostate Health - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

The prostate health market is expected to register a CAGR of 9.1% over the forecast period.

COVID-19 impacted the prostate health market owing to the disruptions in elective treatment of prostate diseases during the initial phase of the pandemic worldwide. COVID-19 was also reported to have an adverse impact on people with prostate cancer. For instance, the review article published in the Journal of Prostate Cancer and Prostatic Diseases in May 2021 stated that SARS-CoV-2 could possibly damage the prostate and worsen benign prostatic hyperplasia and its related lower urinary tract symptoms through ACE2 signaling, androgen receptors-related mechanisms, inflammation, and metabolic derangement. However, the studied market recovered in the last two years since the restrictions were lifted and elective treatment procedures resumed. The emergence of new variants of COVID-19 has a negligible impact on the prostate health market, and the studied market is expected to register stable growth during the forecast period owing to factors such as rapid technological advances and personalized medicine, rising prevalence of prostate diseases, and increase in research initiatives and funding by government and other agencies.

The market for prostate health is expected to grow during the forecast period owing to the high burden of prostate cancer worldwide and rising awareness among people for early diagnosis. For instance, as per Australian Cancer 2022 statistics, 24.2 thousand new cases of prostate cancer were estimated to be diagnosed in Australia in 2022. Similarly, according to the Canadian Cancer Society, 24.6 thousand Canadian men were expected to be diagnosed with prostate cancer in 2022, representing 20% of all new cancer cases in men in 2022. Therefore, the high burden of prostate cancer is expected to propel the market growth during the forecast period.

Furthermore, the industry's growth is being aided by the rising research activities for the development of innovative treatment by market players. For instance, a report published by Novartis in June 2021 stated that their product 177Lu-PSMA-617 significantly improved overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in the Phase III VISION study. Therefore, the rising research activities by market players for the development and launches of innovative treatments for prostate cancer are expected to propel the market growth during the forecast period.

The strategic initiatives by market players, such as acquisitions, launches, and approvals by market players to expand prostate cancer offerings, are expected to propel the market growth. For instance, in April 2022, Teleflex Incorporated launched the UroLift System in Japan for treating benign prostatic hyperplasia (BPH), or enlarged prostate. Also, in December 2021, the United States FDA approved Entadfi (finasteride and tadalafil) for the treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. Moreover, in May 2021, the European Commission approved Astellas' XTANDITM (enzalutamide) for men with metastatic hormone-sensitive prostate cancer.

Therefore, owing to the aforementioned factors, such as the high burden of prostate cancer and rising research and development activities and product approvals and launches by market players, the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is expected to restrain the market growth.

Prostate Health Market Trends

Radical Prostatectomy is Expected to Witness a Significant Growth Over the Forecast Period

Radical prostatectomy (RP) is a surgery in which the entire prostate gland, as well as some surrounding tissue, are removed. This surgery gives the patient a life expectancy of 10 years or more according to the age group.

The segment is expected to grow during the forecast period owing to the rising demand for robotic-assisted radical prostatectomy and the benefits and success rate of the procedure. For instance, the article published in Frontiers in Surgery in May 2021 stated that patients undergoing radical prostatectomy have a low risk of serious complications. The fastest recovery occurs within the first year after radical prostatectomy, but long-term improvements are conceivable as well.

Furthermore, the rising research studies indicating the benefits and success rate of radical prostatectomy also contribute to the growth of the segment. For instance, a research article published in the Journal of Urology in February 2022 suggested that radical prostatectomy holds a significant cancer-specific mortality advantage over external beam radiotherapy (EBRT) in the combined National Comprehensive Cancer Network high-risk (HR) patients and its subgroup of Johns Hopkins University very high risk (VHR) subgroup patients. Therefore, research studies indicating the advantage of radical prostatectomy (RP) over other procedures are expected to boost the demand for radical prostatectomy during the forecast period.

Additionally, the rising clinical trials with technologically advanced radical prostatectomy devices significantly contribute to the growth of the segment. For instance, in January 2022, Profound Medical Corporation, a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, successfully treated prostate cancer patients in its first-level clinical trial. The treatment was done with the TULSA procedure (performed with the TULSA-PRO system) with a radical prostatectomy. Such activities boost the demand for radical prostatectomy procedures during the forecast period.

As a result of the aforementioned factors, such as advantages, rising research studies, and launches, the radical prostatectomy segment is expected to witness significant growth throughout the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast period

North America is expected to hold a significant market share owing to factors such as the high burden of prostate cancer, high research and development (R&D) spending, product launches, and approvals, along with the high concentration of market players in the region. For instance, as per the American Cancer Society 2023 report, an estimated 288.3 thousand new prostate cancers will be diagnosed in 2023 in the United States. Therefore, the rising number of prostate cancer in the region is expected to propel the market growth during the forecast period.

Additionally, product launches, mergers, acquisitions, and the presence of market players in the region significantly contribute to the growth of the prostate health market. For instance, in October 2021, Amgen acquired Teneobio Inc. The acquisition will enable significant acceleration and efficiency in the discovery and development of new molecules to treat a wide range of important diseases across Amgen's core Prostate cancer therapeutic areas.

Furthermore, with the rising adoption of minimally invasive procedures and successful treatment, the market is expected to grow during the forecast period. For instance, in June 2022, Olympus conducted one of the first commercial treatments of Benign Prostatic Hyperplasia (BPH) in Canada using its minimally invasive iTind procedure. Such initiatives further fuel the market growth.

Therefore, owing to the above-mentioned factors, such as the high burden of prostate cancer, rising R&D spending, and launches and acquisitions to expand the research activities and development of prostate cancer treatment by market players, the growth of the studied market is anticipated in the North America Region.

Prostate Health Industry Overview

The prostate health market is moderately competitive in nature due to the presence of several companies operating globally as well as regionally. Some market players are Novartis AG, Teleflex, Siemens Healthcare GmbH, Elekta, Bayer AG, Theragenics, Clovis Oncology, Pfizer Inc., and Sanofi

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support